MX2010012811A - Proteinas de union al receptor de interleucina-21. - Google Patents

Proteinas de union al receptor de interleucina-21.

Info

Publication number
MX2010012811A
MX2010012811A MX2010012811A MX2010012811A MX2010012811A MX 2010012811 A MX2010012811 A MX 2010012811A MX 2010012811 A MX2010012811 A MX 2010012811A MX 2010012811 A MX2010012811 A MX 2010012811A MX 2010012811 A MX2010012811 A MX 2010012811A
Authority
MX
Mexico
Prior art keywords
binding
antigen
fragment
binding protein
protein
Prior art date
Application number
MX2010012811A
Other languages
English (en)
Spanish (es)
Inventor
Deborah A Young
Davinder Gill
Laird Bloom
Yulia Vugmeyster
David Lowe
Viia Valge-Archer
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41112652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010012811(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of MX2010012811A publication Critical patent/MX2010012811A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2010012811A 2008-05-23 2009-05-26 Proteinas de union al receptor de interleucina-21. MX2010012811A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5550008P 2008-05-23 2008-05-23
PCT/US2009/045182 WO2009143523A1 (en) 2008-05-23 2009-05-26 Interleukin-21 receptor binding proteins

Publications (1)

Publication Number Publication Date
MX2010012811A true MX2010012811A (es) 2011-05-19

Family

ID=41112652

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010012811A MX2010012811A (es) 2008-05-23 2009-05-26 Proteinas de union al receptor de interleucina-21.

Country Status (20)

Country Link
US (2) US8163884B2 (https=)
EP (1) EP2297199A1 (https=)
JP (1) JP2011523849A (https=)
KR (1) KR20110040773A (https=)
CN (1) CN102105491A (https=)
AR (1) AR071885A1 (https=)
AU (1) AU2009248809A1 (https=)
CA (1) CA2724915A1 (https=)
CL (1) CL2009001284A1 (https=)
CO (1) CO6382184A2 (https=)
IL (1) IL209328A0 (https=)
MX (1) MX2010012811A (https=)
MY (1) MY149448A (https=)
NZ (1) NZ589330A (https=)
PE (1) PE20100141A1 (https=)
RU (1) RU2010152690A (https=)
SA (1) SA109300315B1 (https=)
TW (1) TW201000129A (https=)
WO (1) WO2009143523A1 (https=)
ZA (1) ZA201008335B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
JP6027744B2 (ja) * 2009-12-25 2016-11-16 積水メディカル株式会社 ヒトインスリン測定方法及び測定試薬
US8846603B2 (en) * 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
US9309318B2 (en) 2012-10-17 2016-04-12 Amgen, Inc. Compositions relating to anti-IL-21 receptor antibodies
US20190185559A1 (en) * 2016-09-02 2019-06-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
US12134790B2 (en) 2017-09-27 2024-11-05 Inozyme Pharma, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (NPP1)
US12012441B2 (en) 2020-10-26 2024-06-18 Neptune Biosciences Llc Engineered human IL-21 cytokines and methods for using the same
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7198789B2 (en) 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US7189400B2 (en) 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US6576744B1 (en) 1998-09-23 2003-06-10 Zymogenetics, Inc. Cytokine receptor zalpha11
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
KR100743640B1 (ko) 1999-03-09 2007-07-27 지모제넥틱스, 인코포레이티드 신규한 사이토킨 ｚａｌｐｈａ 11 리간드
WO2000069880A1 (en) 1999-05-18 2000-11-23 Millennium Pharmaceuticals, Inc. Il-9/il-2 receptor-like molecules and uses thereof
ES2279809T3 (es) 2000-04-05 2007-09-01 Zymogenetics, Inc. Receptores de citoquina zalfa11 solubles.
EP1787997A1 (en) 2000-05-11 2007-05-23 Genetics Institute, LLC MU-1, member of the cytokine receptor family
ES2334338T3 (es) 2001-11-05 2010-03-09 Zymogenetics, Inc. Antagonistas de il-21.
US20040016010A1 (en) 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
DK1531850T3 (da) 2002-06-07 2012-06-04 Zymogenetics Inc Anvendelse af 1L-21 og monoklonalt antistof til behandling af solide cancere
US7314623B2 (en) 2002-07-15 2008-01-01 Wyeth Methods and compositions for modulating T helper (Th) cell development and function
NZ542306A (en) * 2003-03-14 2008-04-30 Wyeth Corp Antibodies against human IL-21 receptor and uses therefor
CA2518854A1 (en) 2003-03-21 2004-10-07 Wyeth Treating immunological disorder using agonists of interleukin-21/interleukin-21 receptor
EP1670501A2 (en) 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
EP1753458A4 (en) 2004-05-19 2009-07-22 Wyeth Corp MODULATION OF IMMUNOGLOBULIN PRODUCTION AND ATOPIC DISORDERS
RU2007102287A (ru) 2004-08-05 2008-09-10 Вайет (Us) Антагонисты активности рецептора интерлейкина-21
CN101052419A (zh) * 2004-08-05 2007-10-10 惠氏公司 拮抗白介素－21受体活性
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
WO2008081198A1 (en) 2007-01-05 2008-07-10 Imperial Innovations Ltd Blood assays for predicting inflammatory responses

Also Published As

Publication number Publication date
CN102105491A (zh) 2011-06-22
US20090298167A1 (en) 2009-12-03
US20120264919A1 (en) 2012-10-18
CL2009001284A1 (es) 2009-11-27
WO2009143523A1 (en) 2009-11-26
US8163884B2 (en) 2012-04-24
AU2009248809A1 (en) 2009-11-26
PE20100141A1 (es) 2010-02-22
EP2297199A1 (en) 2011-03-23
CO6382184A2 (es) 2012-02-15
ZA201008335B (en) 2014-04-30
CA2724915A1 (en) 2009-11-26
AR071885A1 (es) 2010-07-21
KR20110040773A (ko) 2011-04-20
JP2011523849A (ja) 2011-08-25
IL209328A0 (en) 2011-01-31
MY149448A (en) 2013-08-30
SA109300315B1 (ar) 2012-08-28
RU2010152690A (ru) 2012-06-27
TW201000129A (en) 2010-01-01
NZ589330A (en) 2012-12-21

Similar Documents

Publication Publication Date Title
US9447182B2 (en) Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
US11525005B2 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
US8178097B2 (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
MX2010012811A (es) Proteinas de union al receptor de interleucina-21.
SA07280062B1 (ar) الاجسام المضادة لـ il -22 الآدمى و استخداماتها
CA2609234A1 (en) Anti-il2 antibodies
KR20240026496A (ko) 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체
US20250282881A1 (en) Antibodies and bispecific binding proteins that bind ox40 and/or pd-l1
KR20160125965A (ko) 신규 인간 tlr2 및 인간 tlr4에 결합하는 이중 특이적 항체
US20240269276A1 (en) Specific binding protein targeting pd-l1 and cd73
EP4276111A1 (en) Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
KR20230158058A (ko) 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도
KR102872375B1 (ko) Tigit에 특이적으로 결합하는 항-tigit 항체, 상기 항체 및 인터루킨-10를 포함하는 융합 단백질 및 이들의 용도
HK1157358A (en) Interleukin-21 receptor binding proteins
WO2024094159A1 (zh) 靶向人源ror1的单域抗体
WO2024230179A1 (zh) 抗人il-15的抗体及其用途
KR20170076332A (ko) 항 Ang2 항체를 포함하는 면역강화제
HK40086025A (en) Anti-human nr1 antibody derivative
HK1157220A (en) Methods of treatment utilizing binding proteins of the interleukin-21 receptor
HK40046942A (en) Antibody targeting cldn18.2, bispecific antibody, adc, and car, and applications thereof
HK40002168A (en) Antibodies targeting fc receptor-like 5 and methods of use

Legal Events

Date Code Title Description
FG Grant or registration